Joel Neal MD Of Stanford University Medical Center Discusses Results Of TAK-788 Trial: Among 28 Patients That Were Enrolled 43% Had A Response, PFS Was 7.3 Months, Drug Was Well Tolerated Overall.
Advertisement
Results Of TAK-788 Trial: Among 28 Patients That Were Enrolled 43% Had A Response, PFS Was 7.3 Months, Drug Was Well Tolerated Overall
By Editor